Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b + ribavirin with or without hormone replacement therapy in postmenopausal women with chronic HCV hepatitis
2008-001260-36Phase 2Active
- Sponsor
- AOU Policlinico di Modena
- Start
- Mar 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatitis C virus infection, hepatic fibrosis and Cirrhosis comparing Peginterferon alfa-2b + ribavirin with Peginterferon alfa-2b + ribavirin + estradiol (2 arms). Primary endpoint: Reduction of fibrosis progression and liver cirrhosis in postmenopausal women with chronic HCV-positive hepatitis. Started Mar 2008; status: active.
02
Drugs
peginterferon alfa-2bribavirinestradiol
03
Conditions
hepatitis C virus infectionhepatic fibrosisCirrhosis
Beyond the preview
Go deeper on 2008-001260-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001260-36.